VU70 Stock Overview
Through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of nutraceutical products in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Doseology Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.20 |
| 52 Week High | CA$0.37 |
| 52 Week Low | CA$0.01 |
| Beta | 0 |
| 1 Month Change | -12.93% |
| 3 Month Change | 1,920.00% |
| 1 Year Change | -12.17% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| VU70 | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | -35.3% | -0.5% | -0.4% |
| 1Y | -12.2% | 3.9% | 4.2% |
Return vs Industry: VU70 underperformed the German Personal Products industry which returned 5.1% over the past year.
Return vs Market: VU70 underperformed the German Market which returned 5.4% over the past year.
Price Volatility
| VU70 volatility | |
|---|---|
| VU70 Average Weekly Movement | 365.8% |
| Personal Products Industry Average Movement | 4.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: VU70's share price has been volatile over the past 3 months.
Volatility Over Time: VU70's weekly volatility has increased from 279% to 366% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Shawn Balaghi | doseology.com |
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of nutraceutical products in Canada. It provides medicinal mushroom products, including tinctures, powders, and adaptogenic herbal supplements to enhance health with a focus on mental health. The company sells its products online through doseology.com, as well as through various retail chains.
Doseology Sciences Inc. Fundamentals Summary
| VU70 fundamental statistics | |
|---|---|
| Market cap | €1.43m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs VU70 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VU70 income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did VU70 perform over the long term?
See historical performance and comparison